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The Uniocular Drug Trial and Second-Eye
Response to Glaucoma Medications
Tony Realini, MD,1 Robert D. Fechtner, MD,2 Sean-Paul Atreides, MD,3 Stephen Gollance, MD2
Purpose: To determine if the intraocular pressure (IOP) reduction observed in a uniocular trial correlates with
the IOP reduction seen in the fellow eye when the same medication is then administered to the second eye of
patients with glaucoma.
Study Design: Observational case series.
Participants: Fifty-two patients with bilateral glaucoma.
Methods: Glaucoma patients underwent uniocular trials of various glaucoma medications, then subsequently received the same drug in the fellow eye. The IOP reduction observed in the first eye was compared with
that observed in the second eye to determine correlation.
Main Outcome Measure: Intraocular pressure reduction in fellow-eye pairs.
Results: Intraocular pressure dropped a mean of 5.7⫾3.8 mmHg (mean ⫾ standard deviation) in the first eye
after a uniocular trial, and 2.8⫾3.3 mmHg in the second eye after bilateral use. Regression analysis demonstrated
a poor correlation between first-eye and second-eye response to the same medication (r2 ⫽ 0.0174). To minimize
possible contralateral IOP effects of first-eye therapy, a subset of 26 patients treated with latanoprost (which has
little if any contralateral IOP effect, due to rapid systemic metabolism) was studied, with no improvement in
correlation (r2 ⫽ ⫺0.0023).
Conclusion: Uniocular trials of glaucoma medications do not adequately predict second-eye IOP responses
to the same medications. If both eyes of a glaucoma patient require IOP reduction, one should not assume that
magnitudes of response will be equal in both eyes. The effect of a given medicine must be assessed independently for each eye. Ophthalmology 2004;111:421– 426 © 2004 by the American Academy of Ophthalmology.

The uniocular drug trial, also called the monocular drug
trial, is a valued tool in glaucoma management. The textbooks of Shields1; Becker-Shaffer2; and Ritch, Shields, and
Krupin3 all recommend employing the uniocular drug trial
to assess individual patient responses to glaucoma medications. At least one major clinical trial has also required
uniocular trials in its protocol.4
In a uniocular drug trial, a patient receives a given
medication in one eye only. After a treatment period long
enough to achieve a steady-state effect, the reduction from
baseline in intraocular pressure (IOP) in the treated eye is
assessed. If an acceptable IOP reduction has been achieved
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in the first eye, the drug is deemed effective in the patient,
and both eyes are subsequently treated with the drug. The
IOP reduction in the second eye to receive the drug is
assumed to be approximately equivalent to the first-eye
response, and is not typically assessed after bilateral therapy
is initiated.
This study was undertaken to determine if the IOP reduction observed in a uniocular trial correlates with the IOP
reduction seen in the fellow eye when the same medication
is then administered to the second eye of patients with
glaucoma.

Materials and Methods
This study was approved by the Human Research Advisory Committee at the University of Arkansas for Medical Sciences and the
Institutional Review Board at the University of Medicine and
Dentistry of New Jersey.
Medical records of glaucoma patients seen in university-based
glaucoma specialty practices were reviewed. Inclusion criteria for
eligible patients included age 18 to 100 years; diagnosis of glaucoma in both eyes; and progressive addition of a topical antiglaucoma medication, first in one eye, then in the second eye, with IOP
determination before and after use of the medication in each eye.
Once identified, data collected from the charts included demographic information, type of glaucoma, ocular medications, and
pertinent IOP readings from the ocular examinations at which the
uniocular trial was commenced, when the uniocular trial was
assessed and second-eye treatment initiated, and when the patient
ISSN 0161-6420/04/$–see front matter
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Table 1. Flow Diagram for Data Collection Sequence
A. Sequence for 43 patients
Visit A
Visit B
Visit C
B. Sequence for 9 patients
Visit A
Visit B
Visit C
Visit D

First-eye baseline IOP established
First-eye treatment started
First-eye IOP change determined
Second-eye baseline determined
Second-eye treatment started
Second-eye IOP change determined
First-eye baseline IOP established
First-eye treatment started
First-eye IOP change determined
Second-eye baseline determined
Second-eye treatment started
Second-eye IOP change determined

IOP ⫽ intraocular pressure.

next returned using the medication in both eyes. In most cases,
these were 3 consecutive visits. In 9 cases, the medication was not
added to the second eye on the uniocular trial assessment visit, but
was added at a later visit; in these cases, the first-eye uniocular IOP
effect was assessed at the 2 consecutive visits beginning with
addition of medication to the first eye, and the second-eye effect
was assessed at the 2 consecutive visits beginning with addition of
medication to the second eye (Table 1).
Although specific time frame data between visits were not
collected, in general we allow 4 to 6 weeks between the initiation
of treatment and the assessment of treatment effect in the uniocular
trial; once the medication is added to the fellow eye, the IOP
reduction in the fellow eye is typically assessed at the next scheduled visit, 3 to 4 months later.
Data analysis included linear regression analysis using the
Pearson correlation coefficient, r. P values of ⱕ0.05 were considered statistically significant. Analysis was performed on the entire
cohort. Subset analysis of patients treated with latanoprost was
performed to eliminate the potential contralateral crossover effect
(latanoprost is unlikely to have a contralateral IOP-lowering effect5). A separate subset analysis of patients with primary openangle glaucoma (POAG) was performed to determine if the type of
glaucoma affected symmetry of IOP responses between fellow
eyes of glaucoma patients. An additional subset analysis of patients with no history of glaucoma surgery (laser or incisional) was
undertaken to exclude prior glaucoma surgery as a source of
noncorrelation.

Results
Fifty-two eligible charts were identified and included in this analysis. Overall, 73.1% were female, 71.2% were white, and the mean
age (⫾ standard deviation [SD]) was 66.0⫾14.0 years. Table 2
shows the medications used in the uniocular trials analyzed in this
report.

Does the First-Eye Response Predict the SecondEye Response?
Among the 52 first-treated eyes undergoing uniocular trials with
various medications, mean IOP (⫾ SD) dropped from a pretrial
baseline of 22.4 (⫾5.2) mmHg to 16.7 (⫾4.3) mmHg, a 5.7mmHg (25.4%) reduction. When the same medication was then
added to the second eye of each patient, mean IOP in the second
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Table 2. Patient Characteristics and Drugs Used in Uniocular
Trials
Diagnosis [n (%)]
Primary open-angle glaucoma
Glaucoma suspect
Chronic angle-closure glaucoma
Normal tension glaucoma
Pigmentary glaucoma
Gender [n (%)]
Female
Male
Race [n (%)]
White
Black
Other
Median age (yrs)
Medication class used in trial [n (%)]
Prostaglandin analogue
␤-blocker
Carbonic anhydrase inhibitor
␣-Adrenergic agonist
␤-blocker–carbonic anhydrase inhibitor fixed combination
Enrollment site [n (%)]
Little Rock
Newark

31 (59.6)
12 (23.1)
5 (9.6)
3 (5.8)
1 (1.9)
38 (73.1)
14 (26.9)
37 (71.1)
13 (25)
2 (3.8)
67
27 (51.9)
14 (26.9)
5 (9.6)
4 (7.7)
2 (3.8)
36 (69.2)
16 (30.8)

eye dropped from pretreatment baseline of 19.7 (⫾4.2) mmHg to
16.9 (⫾3.7) mmHg, a 2.8-mmHg (14.2%) reduction. The Pearson
correlation coefficient, r, for the correlation between IOP reduction
in the first and second eyes was 0.13 (r2 ⫽ 0.017, P ⫽ 0.352),
demonstrating essentially no correlation between the magnitude of
IOP responses of fellow eyes (Fig 1).
Given that the average IOP in the second-treated eye before
treatment was lower than that of the first-treated eye before treatment, it was possible that a smaller absolute IOP change might
represent an equivalent percent change in IOP. We repeated the
analysis using the percent IOP change from baseline, and found
that first-treated eyes experienced a mean individual IOP reduction
of 25%, compared with a 13% mean individual IOP reduction in
second-treated eyes. The Pearson correlation coefficient and its
square for the correlation between percent IOP reduction in fellow
eyes were 0.17 and 0.03, respectively (P ⫽ 0.22).

Does a Contralateral Crossover Effect Affect
Predictive Ability of the Uniocular Trial?
We separately analyzed a subset of 26 patients treated with latanoprost, which is unlikely to have a contralateral IOP-lowering
effect.5 Among the 26 first-treated eyes undergoing uniocular trials
with latanoprost, mean IOP (⫾ SD) dropped from a pretrial baseline of 20.4 (⫾4.0) mmHg to 15.2 (⫾4.2) mmHg, a 5.2-mmHg
(25.5%) reduction. When latanoprost was then added to the second
eye of each patient, mean IOP in the second eye dropped from a
pretreatment baseline of 18.6 (⫾3.4) mmHg to 15.4 (⫾2.8)
mmHg, a 3.2-mmHg (17.2%) reduction. Comparing IOP reduction
in first and second eyes treated with latanoprost, the Pearson
correlation coefficient was 0.16 (r2 ⫽ 0.024, P ⫽ 0.449), again
demonstrating essentially no correlation between IOP responses of
fellow eyes treated with latanoprost (Fig 2).

Does the Type of Glaucoma Affect Predictive
Ability of the Uniocular Trial?
A subset of 31 patients with POAG was analyzed separately. The
Pearson correlation coefficient, r, for the correlation between IOP

Realini et al 䡠 Uniocular Trial

Figure 1. Correlation of intraocular pressure (IOP) reduction among fellow eyes (n ⫽ 52).

reduction in the first and second eyes was 0.13 (r2 ⫽ 0.017, P ⫽
0.483), demonstrating essentially no correlation between IOP responses of fellow eyes.

Does a History of Glaucoma Surgery Affect
Predictive Ability of the Uniocular Trial?
Six patients in the cohort had undergone unilateral or bilateral laser
trabeculoplasty or trabeculectomy before the uniocular trial. The
subset of 46 patients with no history of laser or incisional glaucoma surgery was analyzed separately. The Pearson correlation
coefficient, r, for the correlation between IOP reduction in the first
and second eyes was 0.13 (r2 ⫽ 0.017, P ⫽ 0.392), demonstrating
essentially no correlation between IOP responses of fellow eyes.

Discussion
The uniocular drug trial has long been used to determine
individual responsiveness to glaucoma medications. Despite
its popularity, the assumptions upon which the uniocular

trial is based have been incompletely characterized. In the
most common interpretation of the uniocular trial, the therapeutic response of the tested drug is determined by subtracting the IOP change in the untreated eye from the IOP
change in the treated eye. The rationale is that, had both
eyes remained untreated, the IOP changes would have been
symmetric in fellow eyes, and that the untreated eye provides an internal control that allows for assessment of
nontherapeutic IOP changes.
This method of interpreting the uniocular trial is multiply
flawed. First, it is well known that some drugs—particularly
␤-blockers— exert a contralateral IOP reduction, most
likely due to systemic absorption and delivery to the fellow
eye.4 Thus, simply subtracting the untreated-eye IOP
change from the treated-eye IOP change will underestimate
the therapeutic effect of the drug. Second, and far more
important, the existing data demonstrate that IOP behavior
in fellow eyes is not symmetric. In a study performed over
4 decades ago, Katavisto6 demonstrated that diurnal IOP
curves for fellow-eyes pairs are often dissimilar in shape,

Figure 2. Correlation of intraocular pressure (IOP) reduction between fellow eyes treated with latanoprost (n ⫽ 26).
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with IOP maxima and minima occurring at different times
of day for each eye. A similar study by Wilensky and
colleagues7 3 decades later demonstrated the same phenomenon: 33% of ocular hypertension patients and 36% of
POAG patients exhibited asymmetry of diurnal curve
shapes between fellow eyes. More recently, a study by
Realini and coworkers8 revealed that spontaneous asymmetric IOP changes between fellow eyes of ⱖ3 mmHg are
extremely common, occurring in over 63% of glaucoma
patients on stable medication regimens.
Using the untreated fellow eye as a control to assess
therapeutic IOP responses can lead to an interpretive quagmire. Consider the following clinical example: a patient
with untreated IOPs of 22 mmHg in both eyes begins
treatment in the right eye, and 1 month later, IOPs are 24
mmHg in the right eye and 30 mmHg in the left. Using the
untreated left eye as a control, we determine that the medication lowered IOP 6 mmHg (treated eye response minus
untreated eye response gives ⫹2 ⫺ ⫹8 ⫽ ⫺6), despite the
indisputable fact that the IOP in the treated eye is higher on
medication than it was before treatment! Does one deem the
medication successful and begin treatment bilaterally? Obviously, some do: a careful look at Figure 1 will reveal 1
patient whose first-eye IOP change was ⫹2 mmHg, 2 more
patients with no change in IOP after first-eye treatment, and
6 more patients whose IOP was reduced only 1 or 2 mmHg;
in all of these patients, the uniocular trial was deemed a
success, and treatment was begun in the second eye.
We are not confident that fellow eyes can serve as each
others’ controls. This is not to say that IOP is not similar in
fellow-eye pairs. Indeed, very likely it is—on average. Over
time, the average IOP is likely to be very similar in felloweye pairs. But to believe that the IOP in fellow eyes is
identical or nearly so at every instant is not supported and,
in fact, is disproved by the existing literature.
For this reason, our analysis of the uniocular trial in this
study was undertaken using only the information collected
from the treated eye, with no correction for the IOP change
in the untreated fellow eye. Our data show surprisingly but
convincingly that the uniocular drug trial does not predict
second-eye IOP reductions after treatment with the same
medication.
Why might this be? In the uniocular trial flowchart
(Table 1), the IOP change observed between visits A and B
is considered to be the therapeutic change resulting from
treatment with an IOP-lowering drug. But in fact, the IOP
difference between time points A and B represents both a
therapeutic component and a nontherapeutic, spontaneous
component of IOP change. Intraocular pressure in glaucomatous eyes does not remain constant over time; spontaneous changes in IOP in glaucomatous eyes are well established.6 – 8 Similarly, the IOP difference between time points
B and C represents both therapeutic and spontaneous IOP
changes for the second eye treated, and our inability to
demonstrate correlation between first-eye and second-eye
IOP reductions to glaucoma medications might be due to:
●
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asymmetry of the therapeutic component of IOP
change in fellow eyes;

●
●

variability of the spontaneous (nontherapeutic) component of IOP change in fellow eyes;
regression to the mean.

Asymmetry of the Therapeutic Component
We wonder if intereye response differences are related to
asymmetric trabecular meshwork damage and asymmetric
outflow impairment between fellow glaucomatous eyes. In
simplest terms, IOP is determined by outflow resistance in
the trabecular meshwork. Outflow resistance is increased in
eyes with glaucoma. In that glaucoma is uncommonly perfectly symmetric in fellow eyes, it is not unexpected that
IOP should behave asymmetrically as well. Indeed, as noted
above, several studies have demonstrated asymmetry of
various aspects of IOP. Wilensky et al7 and Katavisto6
described asymmetry in the shapes of diurnal IOP curves in
fellow eyes of glaucoma patients, and we have reported
asymmetric IOP fluctuations in fellow eyes of glaucoma
patients.8
It is less obvious, however, how potentially asymmetric
outflow might be related to asymmetric responses to IOPlowering medications. We might expect medications that
act to enhance trabecular outflow to have asymmetric effects in fellow eyes if asymmetric trabecular outflow is
present. We are less certain why medications that act to
reduce aqueous production or to enhance nontrabecular
outflow would have asymmetric effects even in eyes with
asymmetric trabecular outflow.

Variability of the Spontaneous (Nontherapeutic)
Component
Intraocular pressure is a dynamic function and fluctuates in
both normal subjects and glaucoma patients, generally more
so in the latter group. The list of variables that can cause
nontherapeutic changes in IOP (i.e., independent of treatment with glaucoma medications) is long and diverse, and
can include body position, breath holding, and fluid consumption, among countless others. In the present study, the
effect of a given medication in one eye over one time frame
is compared with the effect of the same medication in the
fellow eye over a different time frame. A key problem with
this study design and, indeed, with the concept of the
uniocular trial is that different time frames are subject to
different IOP-changing variables. For instance, a patient
who wore a tight necktie at visit A but no necktie at visits
B and C will have different IOP-affecting variables at play
in the first-eye and second-eye analysis time frames. In this
hypothetical scenario, the therapeutic IOP response to a
given glaucoma medication might have been equivalent in
the eyes, but nontherapeutic IOP changes would potentially
confound data analysis and prevent observation of correlation.

Regression to the Mean
In this retrospective study, uniocular trials were initiated
when the IOP was higher than deemed tolerable. Accordingly, some of the IOP reduction observed after treatment
might be attributable to regression to the mean.
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Regression to the mean occurs when a reduction in IOP
occurs spontaneously rather than therapeutically, and in a
study designed to determine the IOP-lowering efficacy of a
medication, regression to the mean can improve a drug’s
apparent performance. Regression to the mean is a statistical
term and not a physical process. By this, we mean that the
term describes an observed change in IOP but does not offer
an explanation for that change. In fact, regression to the
mean is a catch-all phrase that describes what we choose to
define more causally as the spontaneous (nontherapeutic)
component of IOP change.
Our study’s goal was to demonstrate a difference in IOP
responses of fellow eyes to the same medication. We found
that a difference exists. Because our study was retrospective, each eye underwent IOP reduction based on a threshold
IOP level deemed too high by the treating clinician; it is in
this setting that regression to the mean manifests, and in our
study, regression to the mean should have occurred in both
eyes, which might have increased correlation. Labeling the
difference in fellow-eye responses as a regression to the
mean does not make the difference go away, and more
importantly, labeling it thus offers no explanation regarding
the physiologic basis for the difference.

Does a Contralateral Crossover Effect Affect
Predictive Ability of the Uniocular Trial?
Zimmerman and Kaufman9 proposed that timolol applied in
one eye could lower IOP in the fellow eye via systemic
absorption and delivery. More recently, the contralateral
crossover effect of unilaterally administered ␤-blockers was
quantified in a substudy analysis of the Ocular Hypertension
Treatment Study.4 In this study, mean IOP dropped almost
6 mmHg (22%) in the treated eyes, and 1.5 mmHg (5.8%)
in the untreated contralateral eyes.
In our study, we observed a lower baseline IOP in the
second eye (19.7 mmHg) than in the first eye to be treated
(22.4 mmHg, a 2.5-mmHg difference) and a smaller drop in
IOP in second eyes. As the second-eye baseline was obtained after treating the first eye, we suspected a contralateral crossover effect from the medication instilled in the first
eye.
We investigated this possible source of error in 2 ways.
First, we calculated the IOP difference between fellow eyes
at the preuniocular trial baseline (before either eye received
the uniocular trial drug) and found that the mean IOPs in the
first eye (22.4 mmHg) and second eye (20.4 mmHg) differed by 2 mmHg even before undergoing the uniocular
trial. This difference likely reflects an artifact of the retrospective nature of the study: the eye with the higher pressure
was more likely to be chosen as the first-treated eye. Because the difference in IOPs between eyes was present even
before the uniocular trial, we felt it was unlikely to represent
a therapeutic contralateral crossover effect. To be more
certain, we separately analyzed the 26 patients treated with
latanoprost to see if the correlation improved when the
possibility of a significant crossover effect was eliminated.
(In at least one clinical trial, no crossover effect was seen
with latanoprost.5) In this analysis, the correlation between
first-eye and second-eye IOP reductions to latanoprost was

no better than the correlation for the entire 52-patient cohort. Thus, we feel confident that the differences in first- and
second-eye IOP responses were not attributable to contralateral crossover effects in this study.

Does the Type of Glaucoma Affect Predictive
Ability of the Uniocular Trial?
As previously discussed, it seems intuitive that in hypothetical symmetric glaucoma we might expect symmetric responses to a given medication. In hypothetical asymmetric
glaucoma (worse in one eye than in the other), the converse
is not necessarily true: even if the trabecular outflow is
asymmetrically impaired in fellow eyes, would we really
expect—for instance—a medication that works to enhance
uveoscleral outflow to work differently in these fellow
eyes?
To explore this issue a bit further, we separately analyzed
the data from patients with POAG and from patients with
non-POAG. Symmetric trabecular outflow impairment of
fellow eyes is probably more likely in POAG patients than
in non-POAG patients, and we hoped to demonstrate better
correlation between first- and second-eye IOP responses in
POAG eyes. Alas, although both analyses showed abysmal
correlation, the non-POAG analysis had marginally better
correlation than the POAG eyes (data not shown)!

Does a History of Glaucoma Surgery Affect
Predictive Ability of the Uniocular Trial?
Along the same lines as above, we considered that a patient
with a functioning filtering bleb in one eye might exhibit
asymmetric therapeutic responses, and repeated the analysis
excluding the 6 patients with a history of laser or incisional
glaucoma surgery. Even with these potential confounders
removed, the remaining glaucoma surgery–naı̈ve patients
exhibited no correlation in unilateral and second-eye treatment responses.
This retrospective study is subject to all the limitations
and artifacts known to affect such endeavors. Despite the
limitations, our findings are not merely of marginal statistical significance. No matter how we attempted to clean the
data to minimize artifacts, there simply was no correlation
to be found between the uniocular trial results and the
second-eye IOP response.
We are underway with additional studies to further elucidate these preliminary findings, and we suggest 2 consequences of our current findings. The first is that the uniocular trial is likely to be unhelpful and unnecessary in
glaucoma management. The purpose of the uniocular trial is
to determine if a given drug works for a given patient. This
is based on the assumption that fluctuation in IOP tends to
be similar in both eyes. This is not true. We also have
assumed that if one eye responds well to a medication, the
other will as well. Our data do not support that assumption.
Therefore, none of the assumptions underlying the one-eye
trial are supported by our retrospective studies. Instead, we
need a trial that determines if a given drug works for a given
eye, and the same test must be performed on both eyes of a
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two-eyed patient. The simplest solution is to begin treatment in both eyes simultaneously and assess each eye
separately in terms of IOP response. We cannot generalize
the IOP response to treatment observed in one eye to the
fellow eye.
The second consequence is broader: if fellow eyes have
independent IOP responses to a given drug, we may be able
to reduce the number of subjects enrolled in pharmaceutical
studies by including both eyes of qualified and consenting
patients. This has not been a widely accepted research
practice in the past, due to the impression that fellow eyes
are not independent and might introduce bias into studies.
Our preliminary data, reported here, suggest that fellow
eyes may well be independent in terms of therapeutic responses to IOP-lowering medications, and the benefits of
halving study sample sizes may well outweigh the probably
small risk of bias. Prospective confirmation of these findings is necessary, and could be easily accomplished by post
hoc analysis of data collected during studies such as the
Ocular Hypertension Treatment Study. In that study, patients randomized to the treatment arm underwent uniocular trials during the initiation of treatment. From that
large database, further information about the value of the
monocular trial and the fellow-eye response could be
obtained.
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